Zacks Research Upgrades Keros Therapeutics (NASDAQ:KROS) to “Hold”

Keros Therapeutics (NASDAQ:KROS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other research firms have also weighed in on KROS. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Wall Street Zen raised Keros Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 24th. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Finally, Leerink Partners cut their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Trading Down 1.8%

NASDAQ KROS opened at $11.03 on Thursday. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55. The stock has a 50 day moving average of $10.78 and a 200-day moving average of $11.61. The company has a market cap of $218.72 million, a PE ratio of -2.98 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, sell-side analysts predict that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other news, Director Nima Farzan sold 2,625 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the sale, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. The trade was a 11.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 13,768 shares of company stock valued at $144,979 over the last three months. Company insiders own 12.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the first quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after acquiring an additional 205,022 shares during the period. Creative Planning increased its position in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after acquiring an additional 6,948 shares during the period. Finally, Rhumbline Advisers raised its stake in Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after purchasing an additional 7,146 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.